treatment as fixed effects and subject-within-sequence as a random effect. The least-squares means and stan-dard error of means were derivedfrom the ANOVA or mixed-effectaDay not included in dosing protocol.Table 1. Treatment Sequences in Exenatide Studies Day  1 Day 2 Study A 1 and 23 and 45 and 67 and 8 Study B, Part 1 1 and 23 and 45 and 6 Study B, Part 2 1 and 23 and 45 and 67 and 8Placebo 0.10.10.1 Placebo 0.10.1 Placebo 0.020.050.1. . . a . . . . . .. . . 0.1 Placebo0.01 0.02 0.1Placebo0.05Patients 0.1Placebo0.20.2 0.01 0.01 lacebo 0.05 Placebo0.10.02Day 3Exenatide Dose ( µµµµµg/kg) Day 4 Day 5 Day 7 Day 9 . . . . . .. . .. . . . . . . . .. . . 0.1 0.050.02Placebo0.2 0.2Placebo0.3 . . . . . .. . . . . . . . .. . .. . .0.3 0.30.3Placebo . . . . . .. . . . . . . . .. . .. . .Placebo 0.40.40.4 . . . . . .. . . . . . . . .. . .. . .